Monday, December 28, 2009

ReVance Therapeutics Nabs $25.62

Mountain View-based ReVance Therapeutics has raised $25.62M in a Series D funding, according to a regulatory filing by the firm last week. Source of the new funding was not disclosed. ReVance has previously received funding from Bio*One Capital, Essex Woodlands Healthcare Ventures, Vivo Ventures, Technology Partners, Shepherd Ventures, Palo Alto Investors, Medicis Pharmaceutical Corporation, Bio*One Capital and Pac-Link Ventures. The firm last closed a round of funding in May of 2008 worth $8M. The new funding brings the company's total raised to around $81.0M. ReVance is developing dermatology and aesthetic medicine products. More information »